Cardiovascular Journal of Africa: Vol 31 No 2 (March/April 2020)

11 / 68

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 2, March/April 2020 AFRICA 63
We thank Dr Petra Gaylard, Data Management and Statistical Analysis,
Johannesburg, South Africa, and the Wits Donald Gordon Medical Centre,
University of Witwatersrand for statistical analysis. This publication was
made possible (in part) by a grant from the Carnegie Corporation of New
York. Dr Ahmed Vachiat was supported by a research grant from the
Carnegie Foundation. The statements made and views expressed are, however,
solely the responsibility of the authors.
References
1. World Health Organisation. 10 facts on HIV/AIDS. Available from:
2. UNAIDS. HIV and AIDS estimates (2014) Available from: http://www.
3. Gill J, May M, Lewden C, Saag M, Mugavero M, Reiss P, et al. Causes
of death in HIV-1-infected patients treated with antiretroviral therapy,
1996–2006: Collaborative analysis of 13 hiv cohort studies. Clin Infect
Dis 2010; 50(10): 1387–1396.
4. Lang S, Boccara F, Mary-Krause M, Cohen A. Epidemiology of
coronary heart disease in HIV-infected versus uninfected individuals in
developed countries. Arch Cardiovasc Dis 2015; 108(3): 206–215.
5. Becker AC, Sliwa K, Stewart S, Libhaber E, Essop AR, Zambakides
CA, et al. Acute coronary syndromes in treatment-naive black South
africans with human immunodeficiency virus infection. J Interven Card
2010; 23(1): 70–77.
6. Verma S, Anderson TJ. Fundamentals of endothelial function for the
clinical cardiologist. Circulation 2002; 105(5): 546–549.
7. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary
vasodilator dysfunction on adverse long-term outcome of coronary
heart disease. Circulation 2000; 101(16): 1899–1906.
8. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer
G, et al. Late prognostic value of flow-mediated dilation in the brachial
artery of patients with chest pain. Am J Cardiol 2000; 86(2): 207–210.
9. Gokce N, Keaney JF, Jr, Hunter LM, Watkins MT, Nedeljkovic ZS,
Menzoian JO, et al. Predictive value of noninvasively determined
endothelial dysfunction for long-term cardiovascular events in patients
with peripheral vascular disease. J Am Coll Cardiol 2003; 41(10):
1769–1775.
10. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J.
Plasma concentration of soluble intercellular adhesion molecule 1 and
risks of future myocardial infarction in apparently healthy men. Lancet
1998; 351(9096): 88–92.
11. Lafeuillade A, Alessi MC, Poizot-Martin I, Boyer-Neumann C, Zandotti
C, Quilichini R, et al. Endothelial cell dysfunction in HIV infection. J
Acquir Immune Defic Syndr 1992; 5(2): 127–131.
12. Graham SM, Rajwans N, Jaoko W, Estambale BB, McClelland RS,
Overbaugh J, et al. Endothelial activation biomarkers increase after
HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts
disease progression. AIDS 2013; 27(11): 1803–1813.
13. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-KrauseM, Costagliola
D, et al. HIV and coronary heart disease: time for a better understand-
ing. J Am Coll Cardiol 2013; 61(5): 511–523.
14. Palella FJ, Jr, Phair JP. Cardiovascular disease in HIV infection. Curr
Opin HIV AIDS 2011; 6(4): 266–271.
15. Conaldi PG, Serra C, Dolei A, Basolo F, Falcone V, Mariani G, et al.
Productive HIV-1 infection of human vascular endothelial cells requires
cell proliferation and is stimulated by combined treatment with interleu-
kin-1 beta plus tumor necrosis factor-alpha. J Med Virol 1995; 47(4):
355–363.
16. Fourie C, van Rooyen J, Pieters M, Conradie K, Hoekstra T, Schutte A.
Is HIV-1 infection associated with endothelial dysfunction in a popula-
tion of African ancestry in South Africa? Cardiovasc J Afr 2011; 22(3):
134–140.
17. Becker AC, Libhaber E, Sliwa K, Stewart S, Essop MR. Markers of
inflammation and endothelial activation in black South Africans with
HIV and acute coronary syndromes. J AIDS HIV Res 2010; 2(6):
104–110.
18. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau
F, Creager MA, et al. Guidelines for the ultrasound assessment
of endothelial-dependent flow-mediated vasodilation of the brachial
artery: a report of the International Brachial Artery Reactivity Task
Force. J Am Coll Cardiol 2002; 39(2): 257–265.
19. Vachiat A, McCutcheon K, Tsabedze N, Zachariah D, Manga P. HIV
and ischemic heart disease. J Am Coll Cardiol 2017; 69(1): 73–82.
20. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube
MP, et al. State of the science conference: Initiative to decrease cardio-
vascular risk and increase quality of care for patients living with HIV/
AIDS: executive summary. Circulation 2008; 118(2): 198–210.
21. Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K, et al .
Acute coronary syndrome in human immunodeficiency virus-infected
patients: characteristics and 1 year prognosis. Eur Heart J 2011; 32(1):
41–50.
22. Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, et al.
Clinical features of acute coronary syndromes in patients with human
immunodeficiency virus infection. Circulation 2004; 109(3): 316–319.
23. Mdege ND, Shah S, Ayo-Yusuf OA, Hakim J, Siddiqi K. Tobacco use
among people living with HIV: analysis of data from Demographic
and Health Surveys from 28 low-income and middle-income countries.
Lancet Glob Health 2017; 5(6): e578–e592.
24. Vlachopoulos C, Aznaouridis K, Bratsas A, Ioakeimidis N, Dima I,
Xaplanteris P, et al . Arterial stiffening and systemic endothelial activa-
tion induced by smoking: The role of COX-1 and COX-2. Int J Cardiol
2015; 189: 293–298.
25. So-Armah K, Freiberg MS. Cardiovascular disease risk in an aging HIV
population: not just a question of biology. Curr Opin HIV AIDS 2014;
9(4): 346–354.
26. Cotter BR. Endothelial dysfunction in HIV infection. Curr HIV/AIDS
Rep 2006; 3(3): 126–131.
27. Murphy R, Costagliola D. Increased cardiovascular risk in HIV infec-
tion: drugs, virus and immunity. AIDS 2008; 22(13): 1625–1627.
28. Graham SM, Mwilu R, Liles WC. Clinical utility of biomarkers of
endothelial activation and coagulation for prognosis in HIV infection: a
systematic review. Virulence 2013; 4(6): 564–571.
29. Pathai S, Lawn SD, Gilbert CE, McGuinness D, McGlynn L, Weiss HA,
et al. Accelerated biological ageing in HIV-infected individuals in South
Africa: a case-control study. AIDS 2013; 27(15): 2375–2384.
30. Stein JH. Cardiovascular risk and dyslipidemia management in
HIV-infected patients. Topics Antiviral Med 2012; 20(4): 129–133; quiz 3–4.
31. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis.
Circulation 2004; 109(23 Suppl 1): III27–32.
32. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart
J 1997; 18(Suppl E): E19–29.
33. Baker JV, Lundgren JD. Cardiovascular implications from untreated
human immunodeficiency virus infection. Eur Heart J 2011; 32(8):
945–951.
34. De Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infec-
tion, HAART, and endothelial adhesion molecules: current perspectives.
Lancet Infect Dis 2004; 4(4): 213–222.
35. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft
J, et al. Methods for evaluating endothelial function: a position state-